Simplify Logo

Full-Time

Global Clinical Lead

Renal Cancer Imaging

Confirmed live in the last 24 hours

Telix Pharmaceuticals

Telix Pharmaceuticals

201-500 employees

Develops targeted radiation therapies for cancer

Biotechnology
Healthcare

Expert

Remote in USA

Category
Diagnostics & Laboratory Professionals
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • Bachelor’s degree in biomedical science or imaging-related field is required, Master’s preferred.
  • 10+ years of experience in clinical imaging using CT and PET
  • 5+ years of experience in clinical development within the pharmaceutical or biotechnology industry
  • Strong knowledge of clinical trial design, methodology, and regulatory requirements
  • Track record of working effectively with imaging CROs and vendor management
  • Experience in authoring clinical study and regulatory documents
  • Experience in oncology
Responsibilities
  • Develop and execute on imaging studies to enable the advancement of diagnostic and therapeutic radiopharmaceuticals
  • Lead development of imaging sections of clinical study documentation and regulatory documents
  • Lead the design, analysis, review, and quality control of imaging data to ensure accuracy and quality
  • Oversight of third-party vendors, such as imaging CROs
  • Collaborate with Global Clinical Leads, Global Program Leads, Biostatistics, Clinical Operations, and other cross-functional colleagues to ensure strategic and effective implementation of novel imaging approaches in clinical studies
  • Prepare and deliver presentations, proposals, and reports for senior management, partners, and other stakeholders
Telix Pharmaceuticals

Telix Pharmaceuticals

View

Telix Pharmaceuticals develops and sells products aimed at improving the diagnosis and treatment of cancer and rare diseases using targeted radiation. Their products work by delivering precise radiation to affected areas, which helps in making better treatment decisions and providing personalized therapy. Unlike many other biopharmaceutical companies, Telix focuses specifically on areas such as urologic oncology, neuro-oncology, musculoskeletal oncology, and bone marrow conditioning, addressing significant unmet medical needs. The company's goal is to enhance patient care while maintaining ethical practices and environmental responsibility, ensuring that they create sustainable value for patients, shareholders, and employees.

Company Stage

Grant

Total Funding

$63.5M

Headquarters

Melbourne, Australia

Founded

2015

Growth & Insights
Headcount

6 month growth

12%

1 year growth

27%

2 year growth

90%
Simplify Jobs

Simplify's Take

What believers are saying

  • Telix's completion of the BLA submission for TLX250-CDx positions it for potential market leadership in kidney cancer imaging.
  • Positive data from the ProstACT SELECT trial for TLX591 indicates promising efficacy in prostate cancer treatment, enhancing the company's therapeutic portfolio.
  • The FDA Fast Track designation for TLX101-CDx for glioma imaging accelerates its path to market, potentially improving outcomes for brain cancer patients.

What critics are saying

  • The recent withdrawal of its IPO due to unfavorable market conditions may impact Telix's financial flexibility and investor confidence.
  • The competitive landscape in biopharmaceuticals, especially in oncology, requires continuous innovation to maintain market position.

What makes Telix Pharmaceuticals unique

  • Telix Pharmaceuticals specializes in targeted radiation therapies, setting it apart from traditional biopharmaceutical companies that may not focus on this innovative approach.
  • The company's robust global supply chain ensures the availability and delivery of its products worldwide, providing a competitive edge in distribution and accessibility.
  • Telix's commitment to sustainability and ethical practices integrates patient care and environmental responsibility into its operations, distinguishing it from competitors.